PRISMA-PET - Primary Staging of Prostate Cancer With PSMA
PRISMA-PET - Primary Staging of Prostate Cancer: A Randomized Controlled Trial Comparing 18F-PSMA-1007 PET/CT to Conventional Imaging
Sponsor: Esbjerg Hospital - University Hospital of Southern Denmark
Terminated
Due to change of EAU guidelines, where PSMA-PET/CT is now recommended for primary staging of prostate cancer. We do not believe we ethically could continue this protocol, when the new examination, that was our intervention, is now the recommended.
Other terminated trials from Esbjerg Hospital - University Hospital of Southern Denmark
- COPD Exacerbation · Phase PHASE4 · Aug 2024
- Complex Regional Pain Syndrome Type I · Phase NA · Jan 2023
- Arthritis, Rheumatoid · Phase PHASE1/PHASE2 · Sep 2022
See all terminations from Esbjerg Hospital - University Hospital of Southern Denmark
Other Prostate Cancer trials with similar outcome
Listed as NCT05123300, this NA trial focuses on Prostate Cancer and remains terminated or withdrawn. Sponsored by Esbjerg Hospital - University Hospital of Southern Denmark, it has been updated 7 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Mar 2025 — Present [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Sep 2024 — Mar 2025 [monthly]
Recruiting NA
-
Aug 2024 — Sep 2024 [monthly]
Recruiting NA
-
Jul 2024 — Aug 2024 [monthly]
Recruiting NA
-
May 2024 — Jul 2024 [monthly]
Recruiting NA
▶ Show 2 earlier versions
-
Apr 2023 — May 2024 [monthly]
Recruiting NA
-
Dec 2021 — Apr 2023 [monthly]
Recruiting NA
First recorded
Oct 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Esbjerg Hospital - University Hospital of Southern Denmark
- Odense University Hospital
- Sygehus Lillebaelt
For direct contact, visit the study record on ClinicalTrials.gov .